Faculty of leading global interventional cardiologists to review results from safety and efficacy studies of Tryton Side Branch Stent
“This symposium presents an exciting opportunity to learn about treating bifurcation lesions from leading interventionists from around the world”
DURHAM, N.C.–(BUSINESS WIRE)–Tryton Medical, Inc., the leading developer of stents designed to treat coronary bifurcation lesions, today announced that the company is sponsoring a clinical symposium and exhibiting at the Transcatheter Cardiovascular Therapeutics (TCT) 2016 meeting at the Walter E. Washington Convention Center in Washington, D.C. October 29 – November 2.
The Tryton clinical symposium, “Establishing the New Standard: Definitive Treatment for Complex Bifurcation Lesions,” will be held in Room 143B on Monday, October 31 from 6:30-8am ET. Martin Leon, MD, director of the Center for Interventional Vascular Therapy at New York-Presbyterian Hospital/Columbia University in New York City, and David Rizik, MD, interventional cardiologist at HonorHealth Heart Group in Scottsdale, AZ, will serve as chairmen of the symposium and will be joined by a faculty including:
- Philippe Généreux, MD, Columbia University Medical Center/Hôpital du Sacré-Coeur de Montréal
- Maciej Lesiak, MD, PhD, University Hospital Poznan, Poznan, Poland
- Jens Flens Lassen, MD, PhD, Rigshospitalet, University of Copenhagen, København Ø, Denmark
- Joel Schneider, MD, NC Heart & Vascular, Raleigh, NC
The faculty will discuss how the Tryton Side Branch Stent might change daily practice after reviewing results from safety and efficacy studies. The symposium will also feature a presentation on the importance of side branch ostial scaffolding in bifurcation lesions involving large side branches (≥2.5mm), and an EU perspective on left main coronary artery disease.
“This symposium presents an exciting opportunity to learn about treating bifurcation lesions from leading interventionists from around the world,” said Shawn McCarthy, president and CEO of Tryton Medical. “The faculty will highlight the significant need for technologies and strategies to achieve more consistent outcomes for bifurcated lesions, particularly when a large side branch is involved. We look forward to a discussion on how the Tryton Side Branch Stent is designed to support complete lesion coverage with a more predictable procedure.”
Tryton will also exhibit at booth 1343 at TCT 2016. For more information, visit http://www.crf.org/tct.
About Tryton Side Branch Stent
Tryton Side Branch Stent System is built using proprietary Tri-ZONE® technology to offer a dedicated strategy for treating bifurcation lesions. Tryton’s cobalt chromium stent is deployed in the side branch artery using a standard single wire balloon-expandable stent delivery system. A conventional drug eluting stent is then placed in the main vessel. Tryton Side Branch Stent has now been used to treat more than 11,000 patients worldwide. The Tryton Side Branch Stent is commercially available in multiple countries within Europe, Middle East & Africa, is investigational in the US, and is not available in Japan.
About Tryton Medical, Inc.
Tryton Medical, Inc., located in Durham, N.C., is the leading developer of novel stent systems for the treatment of bifurcation lesions. The company was founded in 2003 by Aaron V. Kaplan, M.D., professor of medicine at the Geisel School of Medicine/Dartmouth-Hitchcock Medical Center, to develop stents for the definitive treatment of bifurcation lesions. For more information please visit trytonmedical.com/us and follow the company on Twitter at @TrytonMedical1.